DRUG STUDY NAME OF DRUG Cefuroxime ORDERED DOSE MECHANISM OF ACTION INDICA TION -For skin or skin structure

infections, bone and joint infection. -perioperative prevention

CONTRAINDICA TION

ADVERSE REACTIONS

NURSING RESPONSIBILITIES -Assess patients infection before therapy and regularly thereafter. -Be alert for adverse reactions and drug interactions -for oral, instruct patient to take drug exactly as prescribed , even after he feels better -Before giving first dose, ask patient about previous reactions to cephalosporins.

Penicillin potassium

Patients CNS: Dizziness , headache, hypersensitive to malaise, paresthesia drug or other GI: abdominal cramps, anal cephalosporins pruritus, anorexia, diarrhea, dyspepsia, nausea GU: Candidiasis, pruritus Hematologic: eosinophilia, haemolytic anemia, thrombocytopenia, transient neutropenia Respiratory: Dyspnea Skin: Erythematous and maculopapular rashes, urticaria G 2.5 mil u Kills susceptible For moderate Patients CNS: Coma, neuropathy, seizures o hypersensitive to CV: Thrombophlebitis IV q6 bacteria to severe the drug or other Hematologic: Hemolytic anemia, infections penicillins leukopenia Metabolic: severe potassium poisoning

600 mg IV Hinders or kills q8o susceptible bacteria, including many gram- positive organisms and enteric gramnegative bacilli.

Clindamycin(D alacin C)

10 ml q8o Kills susceptible Infection per orem bacteria caused by specific microorganism

Patients hypersensitive to drug or lincomycin -use cautiously in patients with renal or hepatic disease, asthma, history of

CV: Thrombophlebitis EENT: Pharyngitis GI: Abdominal pain, anorexia, constipation, flatulence, vomiting GU: UTI Hematologic: eosinophilia,

Assess patients infection before starting therapy and regularly thereafter to monitor drugs effectiveness - Assess renal, cardiac and vascular conditions with physical exams and laboratory testing before start of therapy -Tell patient to report if rash, fever, or chills develop - Assess patients infection before starting therapy and regularly thereafter to monitor drugs effectiveness - Instruct patient to report diarrhea and to avoid self- treatment because of the risk of life- threatening pseudomembranous

Ibuprofen

GI disease or transient leukopenia significant allergies. Skin: maculopapular rash , urticaria o 7.5ml q6 Relieves pain , -mild to -patients CNS: Aseptic meningitis, for 2 days fever, and moderate pain hypersensitive to the cognitive dysfunction, dizziness , drug or any of its drowsiness, headache per orem inflammation components and in CV: Edema, heart failure, those with nasal peripheral edema polyps, angioedema EENT: Tinnitus, visual and bronchospastic disturbances reaction to aspirin or GI: Epigastric distress, nausea, other NSAIDS occult blood -Use cautiously in GU: Reversible renal failure patients with GI Hematologic: Agranulocytosis, disorders, history of anemia, aplastic anemia, peptic ulcer disease, leukopenia hepatic or renal disease, cardiac Respiratory: Bronchospasm Skin: Pruritus , rash decompensation,

colitis - Tell patient receiving drug IV to report discomfort at infusion site - Assess patients underlying condition before starting therapy - Evaluate patient for relief from pain, fever or inflammation. - Check renal and hepatic function periodically - Give with meals or milk to reduce adverse GI reactions - Warn patient that using drug with aspirin, alcohol or corticosteroids may increase the risk of adverse GI reactions - Teach patient to recognize and report signs and symptoms of GI bleeding such as blood on the stool

Amikacin sulphate

500 mg IV Kills susceptible Q 12O bacteria and many aerobic gram negative organisms.

Infections caused by specific microorganism

hypertension Patients hypersensitive to drug or other aminoglycosides -Use cautiously in patients with impaired renal failure or neuromuscular disorders

CNS: headache, neuromuscular blockade EENT: Ototoxicity GU: Nephrotoxicity Hepatic: Hepatic necrosis

Assess patients infection, hearing, weight, and renal function test values before therapy and regularly therafter - Watch for signs of ototoxicity, including tinnitus , vertigo , hearing loss - Monitor amikacin level. Obtain blood for peak amikacin level 1 hour after I.M. injection - Tell patient to report changes in hearing or urine appearance or elimination pattern - Emphasize importance of drinking 2L of fluid daily, unless contraindicated

Ketorolac Tromethamine

15 mg IV Relieves pain Short term -Patients o q6 and management of hypersensitive to the drug or any of its inflammation pain component; in those with a history of of nasal polyps, angioedema, bronchospastic reactivity or allergic reactions to aspirin or other NSAIDS, in those with advanced renal impairment. -use cautiously in patients in the perioperative period and in patients with hepatic or renal impairment.

CNS: dizziness, drowsiness, headache, insomnia, syncope CV: Edema, hypertension, palpitations EENT: corneal edema, keratitis GI: Diarrhea, dyspepsia, GI pain, nausea GU: Hematuria, polyuria Hematologic: anemia, eosinophilia Skin: Sweating

Assess patients pain before and after drug therapy - -Be alert for adverse reactions and drug interactions - Teach patient to recognize and immediately report signs and symptoms of GI Bleeding such as occult blood - Advise patient to report persistent or worsening pain.